 |
274 Diseases |  |
1060 Trials |
|
1060 Trials |  |
12189 News |  |
| «12...56789101112131415...178179» |
- || lobaplatin (D19466) / AEterna Zentaris, Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal, BRCA Biomarker: Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial. (Pubmed Central) - Apr 19, 2024
Patients with clinical stage II/III TNBC were treated with 5 cycles of anlotinib (12
- | Keytruda (pembrolizumab) / Merck (MSD), Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Enrollment open, Enrollment change, Combination therapy, Metastases: Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (clinicaltrials.gov) - Apr 18, 2024
P1, N=43, Recruiting, Sponsor: M.D. Anderson Cancer Center
Patients with clinical stage II/III TNBC were treated with 5 cycles of anlotinib (12 Suspended --> Recruiting | N=21 --> 43
- ||| Vyloy (zolbetuximab) / Astellas
Enrollment closed, Combination therapy, Metastases: 8951-CL-5201: A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer (clinicaltrials.gov) - Apr 18, 2024
P2, N=393, Active, not recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Suspended --> Recruiting | N=21 --> 43 Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Biomarker, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer (clinicaltrials.gov) - Apr 18, 2024
P2, N=77, Active, not recruiting, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- | albumin-bound paclitaxel / Generic mfg.
Enrollment closed, Phase classification, Trial completion date, Trial primary completion date, Metastases: Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 18, 2024
P=N/A, N=32, Active, not recruiting, Sponsor: Translational Drug Development
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Recruiting --> Active, not recruiting | Phase classification: P2 --> PN/A | Trial completion date: Jun 2024 --> Apr 2025 | Trial primary completion date: Mar 2024 --> Dec 2024
- | New P1/2 trial: FD-IMPACT: Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (clinicaltrials.gov) - Apr 17, 2024
P1/2, N=117, Not yet recruiting, Sponsor: Fudan University
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Phase ? clinical trial of PD-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma (Pubmed Central) - Apr 17, 2024
For patients with programmed death-ligand 1(PD-L1) protein expression combined positive score?20, the experimental group showed higher major pathological response rate than control group (5/5 vs. 0/4, P=0.03). The neoadjuvant therapy of immunotherapy combined with chemotherapy can improve the pathological remission of oral squamous cell carcinoma and the long-term survival benefits and the prognosis of patients.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Metastases: Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: a prospective phase?study (Pubmed Central) - Apr 17, 2024
The most common immune-related adverse event was hypothyroidism (40.0%). Pembrolizumab combined with nab-paclitaxel and platinum shows encouraging antitumor activity accompanied with a manageable safety profile in untreated R/M HNSCC patients in China.
- | ZEN-3694 / Zenith Capital Corp, Keytruda (pembrolizumab) / Merck (MSD)
Trial suspension, Metastases: Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer (clinicaltrials.gov) - Apr 17, 2024
P1, N=57, Suspended, Sponsor: National Cancer Institute (NCI)
Pembrolizumab combined with nab-paclitaxel and platinum shows encouraging antitumor activity accompanied with a manageable safety profile in untreated R/M HNSCC patients in China. Recruiting --> Suspended
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Neo-Sequence 2?NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC (clinicaltrials.gov) - Apr 16, 2024
P2, N=67, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- | adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma, Ameile (aumolertinib) / Jiangsu Hansoh Pharma
Enrollment open, IO biomarker: NEOVADE: Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC (clinicaltrials.gov) - Apr 16, 2024
P2, N=32, Recruiting, Sponsor: Guangdong Provincial People's Hospital
Recruiting --> Suspended Not yet recruiting --> Recruiting
- | Tyvyt (sintilimab) / Eli Lilly, Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche
Trial completion, Trial completion date, Trial primary completion date, Metastases: Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Apr 16, 2024
P=N/A, N=70, Completed, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: May 2025 --> Dec 2023 | Trial primary completion date: May 2025 --> Dec 2023
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal: Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial. (Pubmed Central) - Apr 15, 2024
P2
Longer follow-up to assess survival outcomes and a phase 3 randomised trial are needed to further evaluate the proposed treatment. The China Anti-Cancer Association and the "Leading Goose" Research and Development Project of Zhejiang Province.
- || Cyramza (ramucirumab) / Eli Lilly
Review, Journal, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review. (Pubmed Central) - Apr 15, 2024
RAM?+?PTX as a second-line treatment is effective and associated with an acceptable toxicity profile in patients with advanced or metastatic G/GEA in real-world settings of Japan and South Korea. More studies are recommended to further evaluate effectiveness and safety of RAM or RAM-based therapy, especially after anti-PD-1 therapy, in a wider Eastern Asian population.
- ||| olvimulogene nanivacirepvec (GL-ONC1) / Genelux
Trial primary completion date: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (clinicaltrials.gov) - Apr 15, 2024
P3, N=186, Recruiting, Sponsor: Genelux Corporation
More studies are recommended to further evaluate effectiveness and safety of RAM or RAM-based therapy, especially after anti-PD-1 therapy, in a wider Eastern Asian population. Trial primary completion date: Aug 2024 --> Aug 2025
- || Lartruvo (olaratumab) / Eli Lilly
Clinical, P1/2 data, Journal, Metastases: Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine (Pubmed Central) - Apr 13, 2024
Olaratumab plus chemotherapy failed to improve the OS or PFS in participants with metastatic PDAC. There were no new safety signals.
- | Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Opdivo (nivolumab) / BMS, Cabometyx (cabozantinib tablet) / Exelixis
Trial completion date, Trial primary completion date: Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 12, 2024
P2, N=117, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
There were no new safety signals. Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
- |||||||||| Sulanda (surufatinib) / Hutchmed
New P2/3 trial, Metastases: A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 12, 2024
P2/3, N=482, Not yet recruiting, Sponsor: Hutchmed
- | Trial primary completion date, Surgery, Metastases: NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov) - Apr 11, 2024
P2, N=60, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024 Trial primary completion date: Apr 2024 --> Apr 2025
- | N201 / TCRCure
Phase classification, Trial primary completion date, Metastases: NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Apr 11, 2024
P1, N=18, Recruiting, Sponsor: TCRCure Biopharma Ltd.
Trial primary completion date: Apr 2024 --> Apr 2025 Phase classification: P1/2 --> P1 | Trial primary completion date: Oct 2023 --> Oct 2024
- || Keytruda (pembrolizumab) / Merck (MSD), Talzenna (talazoparib) / Pfizer, Tecentriq (atezolizumab) / Roche
Retrospective data, Review, Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: A network meta-analysis. (Pubmed Central) - Apr 11, 2024
For PD-L1 and BRCA mutation-positive tumors, atezolizumab/pembrolizumab combined with nab-paclitaxel and talazoparib is an effective treatment option. Neutropenia, diarrhea, and fatigue are frequently occurring serious adverse events.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
P2 data, Journal: Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial. (Pubmed Central) - Apr 11, 2024
Neutropenia, diarrhea, and fatigue are frequently occurring serious adverse events. In this single-arm exploratory phase II trial, patients with treatment-na
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
New P2 trial, Surgery, Metastases: PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients (clinicaltrials.gov) - Apr 11, 2024
P2, N=81, Recruiting, Sponsor: Fudan University
- ||| AMG 193 / Amgen
New P1 trial, Combination therapy, Metastases: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) - Apr 11, 2024
P1, N=282, Not yet recruiting, Sponsor: Amgen
- | Sulanda (surufatinib) / Hutchmed
New P2 trial, Metastases: Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 11, 2024
P2, N=40, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
- ||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial completion date, Metastases: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] (clinicaltrials.gov) - Apr 11, 2024
P3, N=557, Active, not recruiting, Sponsor: Daiichi Sankyo
In this single-arm exploratory phase II trial, patients with treatment-na Trial completion date: Mar 2024 --> Oct 2025
- albumin-bound paclitaxel / Generic mfg.
Nab-Paclitaxel in Trans Arterial Chemoembolization for Breast Cancer Liver Metastasis: It is time to add new drugs to TACE () - Apr 10, 2024 - Abstract #ECIO2024ECIO_563;
Trial completion date: Mar 2024 --> Oct 2025 Application of nab-paclitaxel during TACE for the treatment of BCLM, reveals new insight and promising outcomes in local tumor response
- albumin-bound paclitaxel / Generic mfg.
Minimally invasive intratumoral holmium-166 microsphere implantation in patients with pancreatic ductal adenocarcinoma () - Apr 10, 2024 - Abstract #ECIO2024ECIO_517;
P=N/A
Primary endpoints are feasibility, assessed by post-procedural SPECT, and safety, assessed by continuous adverse event monitoring (CTCAE v5.0). For exploratory endpoints, ECOG score, Quality of Life questionnaires (EQ-5D-5L, EORTC QLQ-C30), pain scales, and laboratory examination focused on pancreatic, liver, immune, and renal function are performed at baseline and at every outpatient visit, and tumor response is assessed by RECIST after 16 weeks.
- || Avastin (bevacizumab) / Roche
P1/2 data, Journal, Metastases: A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL). (Pubmed Central) - Apr 10, 2024
All adverse effects were manageable and none resulted in patient death. In conclusion, the nanoparticle albumin-bound paclitaxel + carboplatin + bevacizumab combination is favorable and well tolerated in Japanese patients as first-line treatment for advanced non-squamous non-small cell lung cancer.
- | Tevimbra (tislelizumab-jsgr) / BeiGene
New P4 trial: PILOT: Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage ? Unresectable Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 10, 2024
P4, N=30, Recruiting, Sponsor: The Affiliated Hospital of Qingdao University
- ||||| relacorilant (CORT125134) / Corcept Therap
Enrollment closed, Combination therapy, Monotherapy, Metastases: ROSELLA: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov) - Apr 8, 2024
P3, N=360, Active, not recruiting, Sponsor: Corcept Therapeutics
In conclusion, the nanoparticle albumin-bound paclitaxel + carboplatin + bevacizumab combination is favorable and well tolerated in Japanese patients as first-line treatment for advanced non-squamous non-small cell lung cancer. Recruiting --> Active, not recruiting
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2/3 trial, Metastases: A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Apr 8, 2024
P2/3, N=266, Recruiting, Sponsor: Army Medical Center of PLA
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Review, Journal, Metastases: Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear. (Pubmed Central) - Apr 8, 2024
Recruiting --> Active, not recruiting Liposomal irinotecan (ONIVYDE
- |||| Yutuo (zimberelimab) / Arcus Biosci, Gilead, domvanalimab (AB154) / Arcus Biosci, Gilead
Trial completion date, Trial primary completion date, Combination therapy, Metastases: STAR-121: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 8, 2024
P3, N=720, Recruiting, Sponsor: Gilead Sciences
Liposomal irinotecan (ONIVYDE Trial completion date: Dec 2027 --> Sep 2027 | Trial primary completion date: Dec 2027 --> Sep 2027
- | Enrollment closed, Trial completion date, Trial primary completion date: PASS-01: Pancreatic Adenocarcinoma Signature Stratification for Treatment (clinicaltrials.gov) - Apr 8, 2024
P2, N=150, Active, not recruiting, Sponsor: University Health Network, Toronto
Trial completion date: Dec 2027 --> Sep 2027 | Trial primary completion date: Dec 2027 --> Sep 2027 Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Sep 2026 | Trial primary completion date: Sep 2022 --> Jan 2025
- ||| TTX-030 / AbbVie, Trishula Therap
Trial completion, Combination therapy, Metastases: TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers (clinicaltrials.gov) - Apr 8, 2024
P1, N=185, Completed, Sponsor: Trishula Therapeutics, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Sep 2026 | Trial primary completion date: Sep 2022 --> Jan 2025 Active, not recruiting --> Completed
- || quemliclustat (AB680) / Arcus Biosci, Gilead
Trial completion date, Trial primary completion date, Combination therapy: ARC-8: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies (clinicaltrials.gov) - Apr 8, 2024
P1, N=165, Active, not recruiting, Sponsor: Arcus Biosciences, Inc.
Active, not recruiting --> Completed Trial completion date: Jun 2024 --> May 2027 | Trial primary completion date: Jun 2024 --> May 2027
- | Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Trial initiation date, Metastases: NOVOCURE: Tumor Treating Fields for Locally Advanced NSCLC (clinicaltrials.gov) - Apr 7, 2024
P1, N=30, Recruiting, Sponsor: University of Utah
Trial completion date: Jun 2024 --> May 2027 | Trial primary completion date: Jun 2024 --> May 2027 Suspended --> Recruiting | Initiation date: Nov 2023 --> Apr 2024
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date: MCC-21-NEURO-11: Pembro+Chemo in Brain Mets (clinicaltrials.gov) - Apr 7, 2024
P2, N=3, Active, not recruiting, Sponsor: John L. Villano, MD, PhD
Suspended --> Recruiting | Initiation date: Nov 2023 --> Apr 2024 Trial primary completion date: Feb 2024 --> Jun 2023
- Keytruda (pembrolizumab) / Merck (MSD), Lynparza (olaparib) / Merck (MSD), AstraZeneca
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations () - Apr 5, 2024 - Abstract #SWOGSpring2024SWOG_Spring_65;
Participants must have received at least 16 weeks of first line platinum-based chemotherapy (i.e., FOLFIRINOX, FOLFOX, gemcitabine + nab paclitaxel + cisplatin or gemcitabine + cisplatin) for metastatic disease...Of the 20 participants on the Olaparib + Pembrolizumab arm, 6 have experienced Grade 3 events. Of the sixteen participants on the Olaparib arm, one participant has experienced a Grade 3 event.
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion, Trial primary completion date, Metastases: Study of Pembrolizumab Combined With Chemotherapy in the First Line Therapy for R/M HNSCC in China (clinicaltrials.gov) - Apr 4, 2024
P2, N=67, Completed, Sponsor: Yuankai Shi
Of the sixteen participants on the Olaparib arm, one participant has experienced a Grade 3 event. Trial primary completion date: Mar 2024 --> Aug 2023 | Recruiting --> Completed
- | Kaitanni (cadonilimab) / Akesobio
New P2 trial, Metastases: Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer (clinicaltrials.gov) - Apr 4, 2024
P2, N=59, Not yet recruiting, Sponsor: West China Hospital
- | Tyvyt (sintilimab) / Eli Lilly, Avastin (bevacizumab) / Roche
New trial, Pan tumor, Metastases: A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. (clinicaltrials.gov) - Apr 4, 2024
P=N/A, N=150, Recruiting, Sponsor: Zhejiang Cancer Hospital
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (clinicaltrials.gov) - Apr 4, 2024
P3, N=1200, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial primary completion date: Mar 2024 --> Aug 2023 | Recruiting --> Completed Not yet recruiting --> Recruiting
- || CM24 / Merck (MSD), Purple Biotech, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=79, Active, not recruiting, Sponsor: Famewave Ltd.
Not yet recruiting --> Recruiting Trial completion date: Mar 2024 --> Jan 2025 | Trial primary completion date: Feb 2024 --> Dec 2024
- || Tevimbra (tislelizumab-jsgr) / BeiGene, LYT-200 / PureTech
Trial completion date, Trial primary completion date, Combination therapy, Metastases: LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=80, Recruiting, Sponsor: PureTech
Trial completion date: Mar 2024 --> Jan 2025 | Trial primary completion date: Feb 2024 --> Dec 2024 Trial completion date: Sep 2024 --> Jan 2025 | Trial primary completion date: Mar 2024 --> Sep 2024
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy (clinicaltrials.gov) - Apr 4, 2024
P2, N=80, Recruiting, Sponsor: Wake Forest University Health Sciences
Trial completion date: Sep 2024 --> Jan 2025 | Trial primary completion date: Mar 2024 --> Sep 2024 Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
- | Keytruda (pembrolizumab) / Merck (MSD), Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Enrollment change, Trial suspension, Combination therapy, Metastases: Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (clinicaltrials.gov) - Apr 4, 2024
P1, N=21, Suspended, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Mar 2025 N=36 --> 21 | Recruiting --> Suspended
- | Enrollment change, Trial completion date, Trial primary completion date: CHAMP: Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer (clinicaltrials.gov) - Apr 4, 2024
P=N/A, N=300, Recruiting, Sponsor: Lund University
N=36 --> 21 | Recruiting --> Suspended N=180 --> 300 | Trial completion date: Sep 2025 --> Sep 2027 | Trial primary completion date: Sep 2024 --> Sep 2026
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
New trial, Grant: Investigator Grant (IG) 2022 27746 (clinicaltrials.gov) - Apr 4, 2024
P=N/A, N=153, Recruiting, Sponsor: IRCCS San Raffaele